ResearcherMedical University of South CarolinaActive in the last 2 years

Rachel A. Burge

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9363-4333; OpenAlex author ID A5067719739. Sources: OpenAlex.

Their work

Papers: 4
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 31

Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 3 papers

Papers 4

PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-4501 ↗
Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… Co-author DOI 10.1158/0008-5472.can-25-0018 ↗
KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Co-author DOI 10.1158/0008-5472.can-25-2630 ↗
A High-Affinity Monoclonal Antibody Against the Pancreatic Ductal Adenocarcinoma Target, Anterior Gradient-2 (AGR2/PDIA17). Co-author DOI 10.3390/antib13040101 ↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

G. Aaron Hobbs · 4 shared papers, 2024–2026 · strength 0.89
- Paper PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. DOI 10.1158/0008-5472.can-24-4501 ↗
- Paper KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvir… DOI 10.1158/0008-5472.can-25-2630 ↗
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
David F. Kashatus · 2 shared papers, 2026 · strength 0.49
- Paper PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. DOI 10.1158/0008-5472.can-24-4501 ↗
- Paper KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvir… DOI 10.1158/0008-5472.can-25-2630 ↗
Todd W. Bauer · 2 shared papers, 2026 · strength 0.49
- Paper PTEN Oxidation Promotes Constitutive PI3K Signaling and Inducible Macropinocytosis in Pancreatic Cancer. DOI 10.1158/0008-5472.can-24-4501 ↗
- Paper KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvir… DOI 10.1158/0008-5472.can-25-2630 ↗
Thomas B. McFall · 2 shared papers, 2026 · strength 0.42
- Paper KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvir… DOI 10.1158/0008-5472.can-25-2630 ↗
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
Channing J. Der · 2 shared papers, 2026 · strength 0.42
- Paper KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvir… DOI 10.1158/0008-5472.can-25-2630 ↗
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
Lu Han · 1 shared paper, 2026 · strength 0.21
- Paper KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvir… DOI 10.1158/0008-5472.can-25-2630 ↗
Christabelle Rajesh · 1 shared paper, 2026 · strength 0.21
- Paper KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvir… DOI 10.1158/0008-5472.can-25-2630 ↗
Victoria K. Spadafora · 1 shared paper, 2026 · strength 0.21
- Paper KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvir… DOI 10.1158/0008-5472.can-25-2630 ↗
Denis C. Guttridge D · 1 shared paper, 2026 · strength 0.21
- Paper KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvir… DOI 10.1158/0008-5472.can-25-2630 ↗
Christopher M Counter · 1 shared paper, 2026 · strength 0.21
- Paper KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvir… DOI 10.1158/0008-5472.can-25-2630 ↗
Michael Anthony Hollingsworth · 1 shared paper, 2026 · strength 0.21
- Paper KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvir… DOI 10.1158/0008-5472.can-25-2630 ↗
Michael C. Ostrowski · 1 shared paper, 2026 · strength 0.21
- Paper KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvir… DOI 10.1158/0008-5472.can-25-2630 ↗
Nikki K. Lytle · 1 shared paper, 2026 · strength 0.21
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
Yongwoo David Seo · 1 shared paper, 2026 · strength 0.21
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
William Adrian Hall · 1 shared paper, 2026 · strength 0.21
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
Sam Z. Thalji · 1 shared paper, 2026 · strength 0.21
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
Ben George · 1 shared paper, 2026 · strength 0.21
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
Daniel Dorbin · 1 shared paper, 2026 · strength 0.21
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
Mohammed Aldakkak · 1 shared paper, 2026 · strength 0.21
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
Beth E. Erickson · 1 shared paper, 2026 · strength 0.21
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
Douglas B. Evans · 1 shared paper, 2026 · strength 0.21
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
Susan Tsai · 1 shared paper, 2026 · strength 0.21
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
Kathleen K. Christians · 1 shared paper, 2026 · strength 0.21
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
Mandana Kamgar · 1 shared paper, 2026 · strength 0.21
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗
Razelle Kurzrock · 1 shared paper, 2026 · strength 0.21
- Paper Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapi… DOI 10.1158/0008-5472.can-25-0018 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.